Cambio - Excellence in Molecular Biology

Search
Biopharma Quality Control

Biopharma Quality Control : Mycoplasma and Bacteria Testing

Regulatory Mycoplasma Testing

Detection of mycoplasma contamination in cell culture and cell culture derived products with Venor®GeM mycoplasma detection kits.

 

  • Ready-to-use lyophilized kit components simplify logistics and storage
  • Easy-to-use protocol
  • Different versions for conventional PCR, real-time PCR or digital PCR*
  • Validated according to EP 2.6.7, JP G3, USP <63> and USP <1071>
  • TaqMan® probes ensure the highest level of PCR specificity
  • Detect > 100 mycoplasma species
  • Lyophilized, non-infectious mycoplasma sensitivity standards, each containing 10 or 100 CFU of the chosen Mycoplasma species

Mycoplasma, being the smallest known self-replicating bacteria, are capable of infecting a wide range of cell cultures used in the production of biopharmaceuticals, thus posing a significant threat to the safety and efficacy of biopharmaceutical products.

The implementation of robust mycoplasma testing protocols is essential to ensure the safety and quality of biopharmaceutical products. Early detection and mitigation of mycoplasma contamination can prevent costly production delays, product recalls, and potential harm to patients. Therefore, biopharmaceutical manufacturers must employ validated mycoplasma testing methods as part of their quality control procedures. PCR-based methods have become the preferred choice for mycoplasma testing due to their high sensitivity, specificity, and rapid time-to-result.

Minerva Biolabs has developed several mycoplasma detection kits that are specially designed for institutions and companies involved in testing mycoplasma contamination according to EP 2.6.7, USP <63> and JP G3.

The kits enable rapid and reliable identification of mycoplasma in cell culture and cell culture derived biologicals, like ATMPs. All Mollicutes (Mycoplasma, Acholeplasma, Spiroplasma) species so far described as contaminants of cell cultures and media components are specifically detected by amplification of a highly conserved rRNA operon, or more specifically, the 16S rRNA coding region in the mycoplasma genome.

Explore our innovative, robust and highly sensitive mycoplasma detection kits for conventional PCR, real-time PCR or digital PCR* that has been effectively validated according to EP 2.6.7, USP <63> and JP G3.

(* according products will be released soon. Subscribe to our newsletter to get notified.)

Dowload our flyer for product feature comparison.

"Which kit to choose?"

 

Venor® Mycoplasma dPCR

Venor® Mycoplasma dPCR enables rapid and reliable detection of mycoplasma in cell cultures, - EP 2.6.7 (12.2) and USP <77> compliant

Minerva Biolabs

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
111-0001Venor® Mycoplasma dPCR24 reactions �446.20 Quantity
Add
111-0002Venor® Mycoplasma dPCR96 reactions �1,621.50 Quantity
Add

Venor® Mycoplasma dPCR

 

Venor® Mycoplasma dPCR enables rapid and reliable detection of mycoplasma in cell cultures, biopharmaceutical products and ATMPs with digital PCR.
- EP 2.6.7 (12.2) and USP <77> compliant
- Highest sensitivity on market through detection of both RNA and DNA
- Compatible with QIAcuity® digital PCR system
- Fast results in < 3 h

Product Description

Venor® Mycoplasma dPCR is a digital PCR assay for the rapid, sensitive, and reliable detection of mycoplasma contamination in cell cultures, cell culture-derived biologicals, and Advanced Therapy Medicinal Products (ATMPs). The assay has specifically been developed for use with the QIAcuity® digital PCR system and is validated according to EP 2.6.7 (12.2), USP <77>, and in compliance with ICH Q2(R2), meeting criteria for specificity, robustness, and sensitivity with detection limits of ≤ 10 CFU/ml and < 100 GC/ml.

Venor® Mycoplasma dPCR specifically detects mycoplasma by amplifying the highly conserved 16S rRNA coding region of the mycoplasma genome. This enables broad and reliable detection of Mollicutes, including the species listed in the EP and USP. An integrated reverse transcription step allows the assay to detect both mycoplasma DNA and RNA, significantly increasing analytical sensitivity and supporting the detection of low-level contamination.

The kit includes a positive control and an internal control. The external positive control (EPC) / extraction inhibition control (EIC) is not included in the kit. For this purpose, we recommend using 100GC®, 10CFU®, or 100CFU® Mycoplasma Standards.

For product-specific validation (“test for inhibitory substances” or “method suitability test”), we recommend using 100GC® or 10CFU® Mycoplasma Standards.

 

SDS.pdf

 

Specifications

Application Mycoplasma detection
Application areas
  • QC release of biopharmaceuticals and ATMPs
  • QC of cell cultures
Contents
  • Mycoplasma Mix
  • Positive Control
  • Internal Control
  • dPCR grade Water
Compliance EP 2.6.7, USP <77>, JP18 G3
Validation report available
Time-to-result < 3 h
PCR type Digital PCR with reverse transcription
Compatible devices QIAcuity® digital PCR device
Detection limit (LOD) ≤ 10 CFU/ml
< 100 GC/ml
Detection spectrum ≥ 130 mollicutes
Control system
  • Positive control
  • Internal control
Number of reactions
  • 111-0001: 24 reactions
  • 111-0002: 96 reactions
Price per reaction
  • 111-0001: €17.79
  • 111-0002: €16.16
Required equipment
and consumables
  • QIAcuity® digital PCR device
  • QIAcuity® Nanoplate 26k
  • QIAcuity® OneStep Advanced Probe Kit
  • 1.5 ml reaction tubes
  • PCR tubes
  • Centrifuge
  • Pipettes
  • Vortex mixer
  • Venor® Mycoplasma Extraction
Optional for product-specific validation and as EPC/EIC: 10CFU®/100CFU®/100GC® Mycoplasma Standards
(Please refer to the manual for complete list and recommendations)
Storage 2-8 °C; ≤ –18 °C after opening or rehydration
Shipping Ambient temperature
Shelf life (max.) 18 months

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200